Online inquiry

IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11044MR)

This product GTTS-WQ11044MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2&ERBB3 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3; NM_001005915.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064; 2065
UniProt ID P04626; P21860
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11044MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7715MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ9406MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ6093MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ10943MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ1939MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ12853MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ12275MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ5684MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDX-011 (DOX)
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW